Lung Screen Uptake Trial: results from a single lung cancer screening round

Mamta Ruparel, Samantha L Quaife, Jennifer L Dickson, Carolyn Horst, Sophie Tisi, Helen Hall, Magali Taylor, Asia Ahmed, Penny Shaw, Stephen Burke, May-Jan Soo, Arjun Nair, Anand Devaraj, Karen Sennett, Stephen W Duffy, Neal Navani, Angshu Bhowmik, David R Baldwin, Sam M Janes, Mamta Ruparel, Samantha L Quaife, Jennifer L Dickson, Carolyn Horst, Sophie Tisi, Helen Hall, Magali Taylor, Asia Ahmed, Penny Shaw, Stephen Burke, May-Jan Soo, Arjun Nair, Anand Devaraj, Karen Sennett, Stephen W Duffy, Neal Navani, Angshu Bhowmik, David R Baldwin, Sam M Janes

Abstract

The Lung Screen Uptake Trial tested a novel invitation strategy to improve uptake and reduce socioeconomic and smoking-related inequalities in lung cancer screening (LCS) participation. It provides one of the first UK-based 'real-world' LCS cohorts. Of 2012 invited, 1058 (52.6%) attended a 'lung health check'. 768/996 (77.1%) in the present analysis underwent a low-dose CT scan. 92 (11.9%) and 33 (4.3%) participants had indeterminate pulmonary nodules requiring 3-month and 12-month surveillance, respectively; 36 lung cancers (4.7%) were diagnosed (median follow-up: 1044 days). 72.2% of lung cancers were stage I/II and 79.4% of non-small cell lung cancer had curative-intent treatment.

Keywords: imaging/CT MRI etc; lung cancer.

Conflict of interest statement

Competing interests: SMJ, MR, JLD, CH, ST and HH are supported by funding for a large trial of low dose CT screening, called the ‘SUMMIT Study’ by GRAIL Inc. SLQ and NN collaborate on the SUMMIT Study. SMJ has received honoraria from AstraZeneca, BARD1 Bioscience and Janssen for being an Advisory Board Expert and travel to a US conference. SMJ received grant funding from Owlstone for a separate research study and has a family member who has a financial association with AstraZeneca. MR has received travel funding for a conference from Takeda and an honorarium for planning and speaking at educational meetings from AstraZeneca.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.

Figures

Figure 1
Figure 1
Flow chart of invitees and participants demonstrating numbers identified, invited, enrolled, eligible for LDCT and that completed a LDCT examination. DNA, did not attend; LDCT, low-dose CT; LLP, Liverpool Lung Project; MDT, multidisciplinary team; PLCOm2012, Prostate, Lung, Colorectal and Ovarianstudy model 2012; USPSFT, United States Preventive Services Task Force.

References

    1. National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. . Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395–409. 10.1056/NEJMoa1102873
    1. de Koning HJ, van der Aalst CM, de Jong PA, et al. . Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med 2020;382:503–13. 10.1056/NEJMoa1911793
    1. Pastorino U, Silva M, Sestini S, et al. . Prolonged lung cancer screening reduced 10-year mortality in the mild trial: new confirmation of lung cancer screening efficacy. Ann Oncol 2019;30:1162–9. 10.1093/annonc/mdz117
    1. Kovalchik SA, Tammemagi M, Berg CD, et al. . Targeting of low-dose CT screening according to the risk of lung-cancer death. N Engl J Med 2013;369:245–54. 10.1056/NEJMoa1301851
    1. Black WC, Gareen IF, Soneji SS, et al. . Cost-effectiveness of CT screening in the National lung screening trial. N Engl J Med Overseas Ed 2014;371:1793–802. 10.1056/NEJMoa1312547
    1. Crosbie PA, Balata H, Evison M, et al. . Implementing lung cancer screening: baseline results from a community-based 'Lung Health Check' pilot in deprived areas of Manchester. Thorax 2019;74:405–9. 10.1136/thoraxjnl-2017-211377
    1. Quaife SL, Ruparel M, Beeken RJ, et al. . The Lung Screen Uptake Trial (LSUT): protocol for a randomised controlled demonstration lung cancer screening pilot testing a targeted invitation strategy for high risk and 'hard-to-reach' patients. BMC Cancer 2016;16:281. 10.1186/s12885-016-2316-z
    1. Quaife SL, Ruparel M, Dickson JL, et al. . Lung screen uptake trial (LSUT): randomized controlled clinical trial testing targeted invitation materials. Am J Respir Crit Care Med 2020;201:965–75. 10.1164/rccm.201905-0946OC
    1. Guideline Development Group The British thoracic Society guidelines on the investigation and management of pulmonary nodules. Thorax 2015;70:794–8. 10.1136/thoraxjnl-2015-207221
    1. Baldwin DR, White B, Schmidt-Hansen M, et al. . Diagnosis and treatment of lung cancer: summary of updated NICE guidance. BMJ 2011;342:d2110. 10.1136/bmj.d2110
    1. Ruparel M, Quaife SL, Dickson JL, et al. . Evaluation of cardiovascular risk in a lung cancer screening cohort. Thorax 2019;74:1140–6. 10.1136/thoraxjnl-2018-212812
    1. Ruparel M, Quaife SL, Dickson JL. Prevalence, symptom burden and under-diagnosis of COPD in a lung cancer screening cohort, 2019. Available: [Accessed 7 Jun 2019].
    1. Ruparel M, Quaife SL, Dickson JL, et al. . Prevalence, symptom burden, and underdiagnosis of chronic obstructive pulmonary disease in a lung cancer screening cohort. Ann Am Thorac Soc 2020;17:869–78. 10.1513/AnnalsATS.201911-857OC
    1. Ruparel M, Quaife SL, Dickson JL, et al. . Is lung cancer screening an opportunity to reduce cardiovascular mortality? 2019;259:A5896.
    1. Horeweg N, van der Aalst CM, Vliegenthart R, et al. . Volumetric computed tomography screening for lung cancer: three rounds of the Nelson trial. Eur Respir J 2013;42:1659–67. 10.1183/09031936.00197712
    1. Horeweg N, van Rosmalen J, Heuvelmans MA, et al. . Lung cancer probability in patients with CT-detected pulmonary nodules: a prespecified analysis of data from the Nelson trial of low-dose CT screening. Lancet Oncol 2014;15:1332–41. 10.1016/S1470-2045(14)70389-4
    1. Field JK, Duffy SW, Baldwin DR, et al. . UK lung cancer RCT pilot screening trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening. Thorax 2016;71:161–70. 10.1136/thoraxjnl-2015-207140
    1. Bechtel JJ, Kelley WA, Coons TA, et al. . Lung cancer detection in patients with airflow obstruction identified in a primary care outpatient practice. Chest 2005;127:1140–5. 10.1016/S0012-3692(15)34459-7
    1. Ten Haaf K, Tammemägi MC, Bondy SJ, et al. . Performance and cost-effectiveness of computed tomography lung cancer screening scenarios in a population-based setting: a Microsimulation modeling analysis in Ontario, Canada. PLoS Med 2017;14:e1002225. 10.1371/journal.pmed.1002225

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner